Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.19% and Operating profit at 5.55% over the last 5 years
2
The company declared negative results in Mar'25 after positive results in Dec'24
3
With ROE of 12.29%, it has a very expensive valuation with a 7.59 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 443,816 Million (Large Cap)
62.00
NA
0.29%
-0.61
12.29%
7.59
Revenue and Profits:
Net Sales:
8,492 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,578 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.91%
0%
-14.91%
6 Months
11.61%
0%
11.61%
1 Year
23.41%
0%
23.41%
2 Years
31.49%
0%
31.49%
3 Years
51.23%
0%
51.23%
4 Years
24.49%
0%
24.49%
5 Years
-18.32%
0%
-18.32%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.19%
EBIT Growth (5y)
5.55%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.57
Tax Ratio
12.26%
Dividend Payout Ratio
18.49%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
99,562.58%
ROE (avg)
135,472.87%
Valuation key factors
Factor
Value
P/E Ratio
62
Industry P/E
Price to Book Value
7.59
EV to EBIT
53.84
EV to EBITDA
48.08
EV to Capital Employed
17.95
EV to Sales
13.66
PEG Ratio
1.92
Dividend Yield
0.29%
ROCE (Latest)
33.33%
ROE (Latest)
12.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
8,491.70
7,145.60
18.84%
Operating Profit (PBDIT) excl Other Income
2,854.70
2,227.40
28.16%
Interest
0.70
10.90
-93.58%
Exceptional Items
124.40
-13.10
1,049.62%
Consolidate Net Profit
2,578.20
1,876.40
37.40%
Operating Profit Margin (Excl OI)
309.00%
279.40%
2.96%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 18.84% vs -7.32% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 37.40% vs 9.05% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
27,726.70
22,600.50
22.68%
Operating Profit (PBDIT) excl Other Income
7,271.20
4,901.20
48.36%
Interest
6.50
6.70
-2.99%
Exceptional Items
108.60
-128.30
184.65%
Consolidate Net Profit
6,337.00
4,277.80
48.14%
Operating Profit Margin (Excl OI)
230.80%
181.70%
4.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 22.68% vs 7.19% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 48.14% vs 12.13% in Dec 2023
About Jiangsu Hengrui Pharmaceuticals Co., Ltd. 
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






